
Osteoporosis is a silent chronic disease that is often not identified until a fragility fracture occurs. A fragility fracture is defined as a fracture after a fall from standing height or less and signals a significantly increased risk of further fractures within the next two years. While fractures of the hip and spine certainly lead to early mortality, there is evidence that any fragility fracture, except for metatarsal, can also lead to early death even with consideration of other risks.
Fragility fractures, especially at the hip, spine, wrist, humerus and pelvis, should be recognised as a clinical red flag. Early intervention following the fracture is essential to reduce the risk of subsequent fractures. Fragility fractures should trigger a fracture risk assessment and may include bone density testing, along with laboratory testing. The outcomes will inform personalised treatment regimens that include information and patient support services related to osteoporosis, lifestyle advice, calcium and vitamin D supplementation, osteoporosis medication tailored to fracture risk, and falls prevention programs incorporating strength, balance and resistance exercises.
Despite the robust evidence supporting this approach, most adults aged 50 years and over are not receiving secondary prevention care after a fragility fracture. Additionally, patients are often excluded from shared decisionmaking which leads to reduced engagement in their health care and poor adherence due to limited understanding of osteoporosis and its implications if not adequately treated.
While every case of fragility fracture warrants secondary fragility fracture prevention (SFFP) strategies, it is particularly crucial to ensure equity of access for both men and women, certain ethnic groups, care home residents, people with cognitive impairment and those living in low socio-economic conditions.
People with the most to gain from effective secondary prevention are those at very high fracture risk (VHFR). Historically, secondary prevention pathways have not integrated end-to-end care delivery of anabolic therapies, often referring these patients to medical specialists outside the SFFP pathway. However, based on recent trials, many healthcare systems are now recommending and reimbursing anabolic therapy as a first line treatment option for those adults at highest fracture risk, as these therapeutic strategies have been shown to be clinically and cost effective.
To realise the expected benefits from secondary prevention, a workforce with the knowledge, skills and expertise to deliver an effective and efficient pathway with good patient experience is required. This FFN Secondary Fragility Fracture Prevention Competency Framework supports health professionals of all disciplines to understand their learning needs to provide high quality fracture prevention care. Assessment is key to ensuring every person who will benefit from anabolic medications gains access.
Quote from a patient who lives with VHFR and was an informant in the development of the Competency Framework:
“I believe that this is an excellent framework, although developed for secondary fragility fracture prevention, has potential to be a framework for other chronic diseases. It gives clarity and invaluable structure to what can appear to be a very confusing system for those involved, from the patient to the expert and for those who govern and provide funding.”
Bibliography
Cosman. F., Lewiecki, E.M., et al. (2024) Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024. Journal of Bone and Mineral Research; 39(10): 1393-1405.
De Mattia, G., MaƯi, M. & Mazzantini, M. (2024). Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024. Clinical and Experimental Rheumatology; 42(7),: 1311-1316.
Inderjeeth, C.A. & Inderjeth, D.C. (2024). The use of anabolic agents in the treatment of osteoporosis: a clinical update. Current Opinion in Endocrinology, Diabetes & Obesity; 31(4): 157-163.
Liu, D-H., Hsu, C-Y et al (2021). Simple self-assessment tool to predict osteoporosis in Taiwanese men. Frontiers in Medicine; 8; 713535.
Montero-Odasso, M., van der Velde, N et al (2022) World guidelines for falls prevention and management for older adults: a global initiative. Age and Ageing, 51(9). Available at https://worldfallsguidelines.com/
Rippl, M., Grupp, P et al (2025). Characteristics and treatment options of 272,152 geriatric patients with very high and high fracture risk. Osteoporosis International; 36:1257–1266.
Su. F-M., Liu, D-H et al. (2015). Development and validation of an osteoporosis self-assessment tool for Taiwan (OSTAi) postmenopausal women – a sub-study of the Taiwan OsteoPorosis survey (TOPS). PlosOne: DOI:10.137
Taia, T-W., Chen, H-Y et al (2024). Asia-Pacific consensus on long-term and sequential therapy for osteoporosis. Osteoporosis and Sarcopenia. 10: 3-10.
Tran, T., Bliuc, D., et al. (2018). Persistence of excess mortality following individual non-hip fractures: a relative survival analysis. Journal of Clinical Endocrinology & Metabolism. 103(9): 3205-3214.

© 2026 Global Fragility Fracture Network | All Rights Reserved I Designed by Aaron Knight